Nu Skin Enterprises Reports Third-Quarter 2020 Results And Raises Annual Guidance

Rhea-AI Summary

Nu Skin Enterprises reported a strong Q3 2020, achieving 19% revenue growth to $703.3 million and 37% earnings per share (EPS) growth, reaching $1.08. The company raised its full-year guidance, anticipating $2.55 to $2.58 billion in revenue. Sales leaders grew by 12% to 68,516, while customer numbers surged 28% to over 1.5 million. The Americas, Pacific, and EMEA regions showed strong growth. The manufacturing segment excelled with 34% growth. Digital transactions now account for 90% of revenue, indicating a shift towards online commerce.

Positive

• 19% revenue growth to $703.3 million.
• 37% EPS growth to $1.08.
• 12% increase in sales leaders to 68,516.
• 28% growth in customer base to 1,539,511.
• 34% growth in manufacturing division.
• Raised full-year revenue guidance to $2.55 to $2.58 billion.

Negative

• Gross margin decreased from 76.2% to 73.9%.
• Selling expenses rose to 39.9%.
• Operating margin fell to 10.6%.

PROVO, Utah, Nov. 4, 2020 /PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE: NUS) today announced third-quarter results of 19 percent revenue growth and 37 percent earnings per share growth and raised its guidance for 2020.

Executive Summary
Q3 2020 vs. Prior-Year Quarter

Revenue:	$703.3 million; +19%     •    Less than (1%) fx impact
Earnings Per Share (EPS):	$1.08; +37%
Sales Leaders:	68,516; +12%
Customers:	1,539,511; +28%

"We continued to build momentum with accelerated results in the third quarter, as we generated revenue and earnings per share well above expectations," said Ritch Wood, chief executive officer. "As we executed on our long-term strategy, we drove double-digit growth in both customers and sales leaders with revenue improvements in all but one reporting segment. We delivered strong double-digit growth in the Americas, Pacific and EMEA regions, with modest growth throughout most of Asia. Mainland China continues to stabilize with sequentially improving revenue, customers and sales leaders, and we remain on track for a return to year-over-year growth in China in the fourth quarter. Our manufacturing division contributed to our results with impressive 34 percent growth.

"We are outpacing our 2020 growth projections due to strong product demand and ongoing digital investments that empower our sales leaders and affiliates to build a socially enabled business. We are also benefitting from the current environment where more individuals are working from home and shopping online. Currently, approximately 90 percent of Nu Skin revenue is coming from digital transactions."

Q3 2020 Year-Over-Year Operating Results                                                                                

Revenue:	$703.3 million compared to $589.9 million     •    Less than (1%) fx impact
Gross Margin:	73.9% compared to 76.2%     •    Nu Skin business was 76.3% compared to 78.6%     •    Impacted by increased freight charges and geographic mix
Selling Expenses:	39.9% compared to 39.3%     •    Nu Skin business was 42.4% compared to 41.5%
G&A Expenses:	23.5% compared to 25.1%
Operating Margin:	10.6% compared to 11.8%     •    Impacted by lower gross margin
Other Income / (Expense):	$0.5 million compared to ($5.0) million
Income Tax Rate:	24.7% compared to 32.1%     •    Benefited by geographic mix
EPS:	$1.08 compared to $0.79

Stockholder Value

Dividend Payments:	$19.2 million
Stock Repurchases:	$20.0 million     •    $342.8 million remaining in authorization

Q4 and Full-Year 2020 Outlook

Q4 2020 Revenue:	$720 to $750 million; +23 to 29%     •    Approximately +1% fx impact
Q4 2020 EPS:	$1.10 to $1.20; +53 to 67%
2020 Revenue:	$2.55 to $2.58 billion; +6 to 7%     •    Approximately (1%) fx impact
2020 EPS:	$3.35 to $3.45; +8 to 11%

"The growth in our core Nu Skin business is generating a great deal of energy ahead of our fourth-quarter ageLOC Boost and Nutricentials product introductions, and we continue to see increasing demand in our manufacturing segment. This gives us confidence that we will have a strong fourth quarter with momentum heading into 2021 when we fully launch these products and continue to extend our socially enabled business throughout our markets," Wood concluded.

Mark Lawrence, chief financial officer, added, "Given our third-quarter results above previous guidance and momentum in the business, we are raising our guidance for the remainder of the year. As we look ahead to the fourth quarter, we anticipate revenue of $720 to $750 million, which includes an approximate 1 percent favorable foreign currency impact, and earnings per share of $1.10 to $1.20. We are raising our 2020 revenue guidance to $2.55 to $2.58 billion, which reflects a negative foreign currency impact of approximately 1 percent, and we anticipate annual earnings per share of $3.35 to $3.45."

Conference Call
The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com. A replay of the webcast will be available at the same URL through Nov. 18, 2020.

About Nu Skin Enterprises, Inc.
Founded more than 35 years ago, Nu Skin Enterprises, Inc. (NSE) empowers innovative companies to change the world with sustainable solutions, opportunities, technologies and life-improving values. The company currently focuses its efforts around innovative consumer products, product manufacturing and controlled environment agriculture technology. The NSE family of companies includes Nu Skin, which develops and distributes a comprehensive line of premium-quality beauty and wellness solutions through a global network of sales leaders in Asia, the Americas, Europe, Africa and the Pacific; and Rhyz, our strategic investment arm that includes a collection of sustainable manufacturing and technology innovation companies. Nu Skin Enterprises is traded on the New York Stock Exchange under the symbol "NUS." More information is available at nuskinenterprises.com.

Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of management's expectations regarding the company's performance, growth, product launches, customers and sales leaders, strategies and initiatives; statements of management's expectations regarding the future status of the COVID-19 pandemic globally and across the company's markets, and government and public behavior in response to such status; projections regarding revenue, earnings per share, foreign currency fluctuations and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "continue," "anticipate," "project," "outlook," "guidance," "plan," "continue," "will," "would," "could," "may," "might," the negative of these words and other similar words.

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

• risk that epidemics, including the ongoing COVID-19 outbreak, and other crises could negatively impact our business;
• adverse publicity related to the company's business, products, industry or any legal actions or complaints by the company's sales force or others;
• risk that direct selling laws and regulations in any of the company's markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company's business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, imposition of fines, or any other adverse actions or events;
• any failure of current or planned initiatives or products to generate interest among the company's sales force and customers and generate sponsoring and selling activities on a sustained basis;
• political, legal, tax and regulatory uncertainties associated with operating in international markets, including Mainland China;
• uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;
• risk of foreign-currency fluctuations and the currency translation impact on the company's business associated with these fluctuations;
• uncertainties regarding the future financial performance of the businesses the company has acquired;
• risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;
• regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements;
• unpredictable economic conditions and events globally, including trade policies and tariffs;
• uncertainties related to interpretation of, and forthcoming regulations under, the recently enacted U.S. tax reform legislation; the company's future tax-planning initiatives; any prospective or retrospective increases in duties on the company's products imported into the company's markets outside of the United States; and any adverse results of tax audits or unfavorable changes to tax laws in the company's various markets; and
• continued competitive pressures in the company's markets.

The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company's beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company's performance. It is calculated by translating the current period's revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period's revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company's revenue from period to period.

The following table sets forth revenue for the three-month periods ended September 30, 2020 and 2019 for each of our reportable segments (U.S. dollars in thousands):

	Three Months Ended September 30,									Constant- Currency
	2020			2019			Change			Change
Nu Skin
Mainland China	$	169,068		$	173,974			(3)%			(4)%
Americas/Pacific		151,465			83,635			81%			90%
South Korea		83,460			79,435			5%			5%
Southeast Asia		84,102			78,963			7%			8%
Japan		70,958			67,197			6%			4%
EMEA		61,411			35,742			72%			67%
Hong Kong/Taiwan		42,265			40,449			4%			—
Other		(314)			(62)			(406)%			(403)%
Total Nu Skin		662,415			559,333			18%			19%
Manufacturing		40,910			30,601			34%			34%
Grow Tech		22			—			100%			100%
Total	$	703,347		$	589,934			19%			19%

The following table sets forth revenue for the nine-month periods ended September 30, 2020 and 2019 for each of our reportable segments (U.S. dollars in thousands):

	Nine Months Ended September 30,									Constant- Currency
	2020			2019			Change			Change
Nu Skin
Mainland China	$	453,096		$	567,795			(20)%			(19)%
Americas/Pacific		353,957			262,932			35%			43%
South Korea		236,094			248,020			(5)%			(2)%
Southeast Asia		220,517			226,853			(3)%			(1)%
Japan		200,549			194,557			3%			2%
EMEA		147,590			120,960			22%			23%
Hong Kong/Taiwan		115,253			124,719			(8)%			(10)%
Other		374			(239)			256%			256%
Total Nu Skin		1,727,430			1,745,597			(1)%			1%
Manufacturing		105,975			91,430			16%			16%
Grow Tech		336			30			1,020%			1,020%
Total	$	1,833,741		$	1,837,057			—			2%

The Company's Customers and Sales Leaders statistics by segment as of September 30, 2020 and 2019 are presented in the following table:

	As of September 30, 2020						As of September 30, 2019						% Increase (Decrease)
	Customers			Sales Leaders			Customers			Sales Leaders			Customers			Sales Leaders
Mainland China		341,386			20,970			317,257			23,776			8%			(12)%
Americas/Pacific		438,889			14,400			229,013			7,760			92%			86%
South Korea		164,256			7,973			169,589			7,363			(3)%			8%
Southeast Asia		163,536			8,357			145,845			7,936			12%			5%
Japan		126,896			6,523			128,373			5,964			(1)%			9%
EMEA		235,202			6,226			147,758			4,060			59%			53%
Hong Kong/Taiwan		69,346			4,067			68,862			4,231			1%			(4)%
Total		1,539,511			68,516			1,206,697			61,090			28%			12%

"Customers" are persons who purchased products directly from the company during the previous three months. Our Customer numbers do not include consumers who purchase products directly from members of our sales force.

"Sales Leaders" are independent distributors, and sales employees and independent marketers in China, who achieve certain qualification requirements.

NU SKIN ENTERPRISES, INC.
Consolidated Statements of Income (Unaudited)
(U.S. dollars in thousands, except per share amounts)
	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Revenue	$	703,347		$	589,934		$	1,833,741		$	1,837,057
Cost of sales		183,374			140,162			463,277			440,854
Gross profit		519,973			449,772			1,370,464			1,396,203
Operating expenses:
Selling expenses		280,695			231,937			735,365			727,473
General and administrative expenses		165,050			147,943			466,232			455,983
Total operating expenses		445,745			379,880			1,201,597			1,183,456
Operating income		74,228			69,892			168,867			212,747
Other income (expense), net		525			(4,979)			(4,068)			(11,153)
Income before provision for income taxes		74,753			64,913			164,799			201,594
Provision for income taxes		18,446			20,823			46,911			68,153
Net income	$	56,307		$	44,090		$	117,888		$	133,441
Net income per share:
Basic	$	1.10		$	0.79		$	2.24		$	2.40
Diluted	$	1.08		$	0.79		$	2.23		$	2.39
Weighted-average common shares outstanding (000s):
Basic		51,308			55,548			52,741			55,507
Diluted		52,243			55,788			52,906			55,950

 

NU SKIN ENTERPRISES, INC.
Consolidated Balance Sheets (Unaudited)
(U.S. dollars in thousands)
	September 30, 2020			December 31, 2019
ASSETS
Current assets:
Cash and cash equivalents	$	366,710		$	335,630
Current investments		11,301			8,413
Accounts receivable, net		60,016			50,378
Inventories, net		270,319			275,891
Prepaid expenses and other		63,916			69,854
Total current assets		772,262			740,166
Property and equipment, net		456,083			453,604
Right-of-use assets		165,749			144,326
Goodwill		196,573			196,573
Other intangible assets, net		74,391			80,321
Other assets		151,653			154,016
Total assets	$	1,816,711		$	1,769,006
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	55,298		$	38,979
Accrued expenses		381,052			290,281
Current portion of long-term debt		30,000			27,500
Total current liabilities		466,350			356,760
Operating lease liabilities		121,439			105,701
Long-term debt		312,664			334,461
Other liabilities		88,785			96,795
Total liabilities		989,238			893,717
Stockholders' equity:
Class A common stock		91			91
Additional paid-in capital		570,491			557,544
Treasury stock, at cost		(1,446,374)			(1,324,826)
Accumulated other comprehensive loss		(83,108)			(85,292)
Retained earnings		1,786,373			1,727,772
Total stockholders' equity		827,473			875,289
Total liabilities and stockholders' equity	$	1,816,711		$	1,769,006

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/nu-skin-enterprises-reports-third-quarter-2020-results-and-raises-annual-guidance-301166603.html

SOURCE Nu Skin Enterprises, Inc.

FAQ

What were the Q3 2020 revenue and earnings per share for Nu Skin (NUS)?

Nu Skin reported Q3 2020 revenue of $703.3 million and earnings per share (EPS) of $1.08.

How much did Nu Skin raise its revenue guidance for 2020?

Nu Skin raised its 2020 revenue guidance to $2.55 to $2.58 billion.

What growth did Nu Skin report in customers and sales leaders for Q3 2020?

Nu Skin reported a 28% increase in customers to 1,539,511 and a 12% increase in sales leaders to 68,516.

What impact did digital transactions have on Nu Skin's revenue?

Approximately 90% of Nu Skin's revenue currently comes from digital transactions.

What growth did Nu Skin's manufacturing segment achieve in Q3 2020?

Nu Skin's manufacturing division achieved a growth of 34% in Q3 2020.